NEW YORK, November 2026 – BlackLight Surgical, a pioneer in intraoperative cancer detection technologies for interventional oncology, has been named a Top Innovator by the New York Venture Summit, which brings together startups and investors in New York City on November 18–19, 2026. BlackLight CEO Frank Cheng will present the company to the summit’s investor audience on November 19.
BlackLight has developed cancer detection technology in collaboration with Cedars-Sinai Medical Center. The technology has received FDA Breakthrough Designation. It visualizes cancer tissue in real time in the operating room, with high precision and without the need to inject dyes or drugs. By helping surgeons see cancer more clearly during an operation, the technology aims to support more complete tumor removal and reduce the need for repeat procedures.
“We are honored that the New York Venture Summit has recognized BlackLight as a top innovator,” said Frank Cheng, CEO of BlackLight Surgical. “We have a technology that can help surgeons see cancer during an operation without adding a dye or a drug. I look forward to sharing that vision with the investors and entrepreneurs at the summit.”
BlackLight Surgical continues to advance its technology toward the clinic and welcomes conversations with clinical, industry, and investment partners.
About BlackLight Surgical
BlackLight Surgical is a pioneer in intraoperative cancer detection technologies for interventional oncology. Developed in collaboration with Cedars-Sinai Medical Center, BlackLight’s system uses dye-free fluorescence imaging to identify cancerous tissue with high precision. The technology has received FDA Breakthrough Device designation. BlackLight’s mission is to help surgeons see cancer clearly during surgery so that patients can be treated successfully with a single operation. For more information, visit bls.life.